Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0560 • ACR Convergence 2023
Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus
Magdalena Riedl Khursigara¹, Nicholas Gold², Thai-Son Tang³, Daniela Dominguez², Marisa Klein-Gitelman⁴, Dafna Gladman⁵, Daniel Goldman⁶, Elizabeth Harvey², Mariko Ishimori⁷, Caroline Jefferies⁷, Diane L. Kamen⁸, Sylvia Kamphuis⁹, Andrea Knight², Chia-Chi Lee⁷, Deborah Levy², Damien Noone², Karen Onel¹⁰, Christine Peschken¹¹, Michelle Petri⁶, Janet Pope¹², Eleanor Pullenayegum², Earl Silverman¹³, Zahi Touma¹, Murray Urowitz¹⁴, Daniel Wallace⁷, Joan Wither¹⁵ and Linda Hiraki², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Medical University of South Carolina, Charleston, SC, ⁹Sophia Children’s Hospital, Rotterdam, Netherlands, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²University of Western Ontario, London, ON, Canada, ¹³Silverman, Toronto, ON, Canada, ¹⁴Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ¹⁵University Health Network, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestation of SLE. Risk factors for lupus nephritis and renal function decline are…
Abstract Number: 0576 • ACR Convergence 2023
Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers
Andrew Concoff¹, Vasileios Kyttaris², Vaneet Sandhu³, Tyler O'Malley⁴, Giorgio Casaburi⁴, Sudha Kumar⁴, Chau Ching Liu⁵, Susan Manzi⁶ and Joeseph Ahearn⁵, ¹Exagen, Los Angeles, CA, ²BIDMC, Boston, MA, ³Loma Linda University, Loma Linda, CA, ⁴Exagen, Vista, CA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease, affecting multiple organ systems with varying severity among patients. SLE presents a diagnostic challenge…
Abstract Number: 0595 • ACR Convergence 2023
Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Richard A. Furie¹, Kenneth Kalunian², Eric Morand³, Ian Bruce⁴, Susan Manzi⁵, Gelareh Atefi⁶, Gary Bryant⁶, Micki Hultquist⁷, Raj Tummala⁷, Gabriel Abreu⁸, Catharina Lindholm⁸ and Hussein Al-Mossawi⁹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²University of California San Diego, La Jolla, CA, ³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁴University of Manchester, Manchester, United Kingdom, ⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁶BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In patients with SLE, nephritis is present in 50%–60% during the first 10 years of disease.1 Renal involvement is associated with poor clinical outcomes…
Abstract Number: 0734 • ACR Convergence 2023
Immune Isoform Atlas: Landscape of Alternative Splicing in Human Immune Cells and Involvement of Dysregulated Alternative Splicing in Autoimmune Diseases
Jun Inamo¹, Akari Suzuki², Mahoko Takahashi Ueda¹, Kensuke Yamaguchi¹, Hiroshi Nishida³, Katsuya Suzuki⁴, Yuko Kaneko⁵, Tsutomu Takeuchi⁶, Hiroaki Hatano⁷, Kazuyoshi Ishigaki⁸, Yasushi Ishihama³, Kazuhiko Yamamoto⁹ and Yuta Kochi¹, ¹Tokyo Medical and Dental University, Tokyo, Japan, ²RIKEN Center for Integrative Medical Science, Kanagawa, Japan, ³Kyoto University, Kyoto, Japan, ⁴Keio University, Shinjuku, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁷Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ⁸RIKEN, Tokyo, Japan, ⁹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: Alternative splicing events play a critical role in the immune system1,2 and one of major causal mechanisms for complex traits including immune-mediated diseases (IMDs),…
Abstract Number: 0887 • ACR Convergence 2023
Dapagliflozin Modulates Inflammation and Germinal Centers in Lupus by Increasing Regulatory T Cells
Javier Rangel-Moreno¹, Maria de la Luz Garcia-Hernandez², Mary O'Connell³, Daria Krenitsky⁴, Maria Fernanda Ossa-Echeverri¹, Mark Lusco⁵, John Looney⁶ and Jennifer Anolik³, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴Division of Allergy, Immunology and Rheumatology/University of Rochester Medical Center, Rochester, NY, ⁵Department of Pathology and Laboratory Medicine/University of Rochester, Rochester, NY, ⁶Division of Allergy, Immunology and Rheumtology, Rochester, NY
Background/Purpose: Nephritis is one of the most severe manifestations of lupus, affecting 40-70% of patients. Though immune-targeted therapies have improved, a significant number of patients…
Abstract Number: 0907 • ACR Convergence 2023
Epstein Barr Virus Reactivation May Associate with Transition from Incomplete to Systemic Lupus Erythematosus
Benjamin Jones¹, Carla Guthridge¹, Marci Beel¹, Catriona Wagner², Stan Kamp¹, Cristina Arriens³, Joan Merrill¹, Teresa Aberle¹, Nancy Redinger¹, Rebecca Wood⁴, Lauren Guthridge¹, Susan Macwana¹, Wade DeJager¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Patients with incomplete lupus erythematosus (ILE) have evidence of SLE but do not fulfill SLE classification criteria. Although most ILE patients maintain a relatively…
Abstract Number: 0928 • ACR Convergence 2023
Skewing of B Cell Receptor Repertoire in Unswitched Memory B Cells Is Associated with Disease Activity of Systemic Lupus Erythematosus and Targeted by Belimumab
Keishi Fujio¹, Mineto Ota¹, Masahiro Nakano², Yasuo Nagafuchi³, Satomi Kobayashi¹, Hiroaki Hatano², Ryochi Yoshida¹, Yuko Akutsu¹, Takahiro Itamiya¹, Nobuhiro Ban⁴, Yumi Tsuchida¹, Hirofumi Shoda¹, Kazuhiko Yamamoto⁵, Kazuyoshi Ishigaki⁶ and Tomohisa Okamura⁷, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁶RIKEN, Tokyo, Japan, ⁷Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Despite the involvement of B cells in the pathogenesis of immune-mediated diseases, the biological mechanisms underlying their function are poorly understood. To address this…
Abstract Number: 1214 • ACR Convergence 2023
Using Patient Self-Reported Measures to Predict All-Cause Hospitalization in a Population-Based Lupus Cohort
S. Sam Lim¹, Sandra Wu², Ryan Ross³, Gaobin Bao¹, Megan Richards³, Liisa Palmer³ and Gary Bryant⁴, ¹Emory University, Atlanta, GA, ²AstraZeneca, Hockessin, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that affects the skin, joints, kidneys, lungs, central nervous system, and hematopoietic system. As a…
Abstract Number: 1350 • ACR Convergence 2023
Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Noah Forrest¹, Joshua Waytz², April Barnado³, Megan Clowse⁴, Theresa Walunas¹ and Rosalind Ramsey-Goldman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern Medicine, Chicago, IL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Duke University, Chapel Hill, NC, ⁵Northwestern University, Chicago, IL
Background/Purpose: SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in…
Abstract Number: 1450 • ACR Convergence 2023
Clinical Manifestations and Outcomes in Systemic Lupus Erythematosus Patients Who Received Antiviral Therapy During the COVID-19 Omicron Variant Wave: Results from a Single Center Cohort of Puerto Rico
Lilliana Serrano-Arroyo¹, Rafael Ríos-Rivera², Ariana González-Meléndez² and Luis M. Vilá², ¹Centro Medico Episcopal San Lucas, San Juan, PR, ²University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: The impact of COVID-19 in patients with systemic lupus erythematosus (SLE) has been a subject of great concern. Antiviral therapy has emerged as a…
Abstract Number: 1467 • ACR Convergence 2023
Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mariana Gonzalez-Trevino¹, Jeffrey Yang², Larry J. Prokop³, Gabriel Figueroa-Parra¹ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…
Abstract Number: 1484 • ACR Convergence 2023
Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature
Katarzyna Karpinska-Leydier¹, Arseni Khorochkov², Ambar Morales-Rodriguez¹, Nur Barlas¹, Sait Barlas¹, Abraham Bell¹, Magdy El-Din³ and Shristi Basnyat⁴, ¹Florida State University - Cape Coral Hospital, Cape Coral, FL, ²Poznan University of Medical Sciences, Poznań, Poland, ³Florida State University/Lee physicians group, Cape Coral, FL, ⁴Florida State University/Lee physicians group, Fort Myers, FL
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE). Current investigations implicate microbiome changes in disease pathogenesis, particularly pathobiont expansions of…
Abstract Number: 1501 • ACR Convergence 2023
Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
Eric Morand¹, Coburn Hobar², Samantha Pomponi³, Ravi Koti⁴, Thomas Wegman⁵ and Ronald van Vollenhoven⁶, ¹Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²Bristol Myers Squibb, Bradenton, FL, ³Bristol Myers Squibb, Princeton, NJ, ⁴Syneos Health, Morrisville, NC, ⁵Bristol Myers Squibb, Beaver Falls, PA, ⁶Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis. A…
Abstract Number: 1598 • ACR Convergence 2023
Single-cell Spatial Proteomics Identifies Intraglomerular Myeloid Cells in Membranous Lupus Nephritis
Chen-Yu Lee¹, Caleb Marlin², Xiaoping Yang¹, Tayte Stephens², Alessandra Ida Celia³, Jeff Hodgin⁴, Peter Izmirly⁵, H Michael Belmont⁶, Jill Buyon⁷, Chaim Putterman⁸, Judith James², the Accelerating Medicines Partnership in RA/SLE⁹, Michelle Petri¹⁰, Joel Guthridge², Avi Rosenberg¹¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³John Hopkins University of Medicine, Rome, Italy, ⁴University of Michigan, Ann Arbor, MI, ⁵New York University School of Medicine, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Albert Einstein College of Medicine, Bronx, NY, ⁹Multiple, Multiple, ¹⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹¹Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) leads to end-stage kidney disease (ESKD) in more than 20% of patients despite optimal treatment. Up to 30% of LN patients…
Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Michael A. Smith¹, Dominic Sinibaldi², Saifur Rahman¹, Chia-Chien Chiang², Anna M. Hansen¹, Jill Henault¹, Carlos P. Roca³, Shu Wang¹, Kamelia Zerrouki¹, Rebecca Filippi¹, Christopher Groves¹, Zerai Manna⁴, Jun Chu⁴, Michael Davis⁴, sarthak gupta⁴, Christopher Morehouse¹, Melissa De los Reyes¹, Rachel Ettinger¹, Roland Kolbeck¹, Mariana Kaplan⁵, Miguel A. Sanjuan¹, Richard M. Siegel⁶, sarfaraz Hasni⁴ and Kerry A. Casey¹, ¹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Data Science and AI, AstraZeneca, Gaithersburg, MD, ³Data Science and AI, AstraZeneca, Cambridge, United Kingdom, ⁴Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁶Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].